missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Chlorhydrate de doxorubicine, LoGiCal
Spécification
Specifications
| Nom chimique ou matériau | Doxorubicin Hydrochloride |
| CAS | 25316-40-9 |
| Noms d’analytes ou de composants | Doxorubicin Hydrochloride |
| Conditions d’expédition | Room Temperature |
| Formule moléculaire | C27 H29 N O11 . Cl H |
| Certifications/Conformité | ISO 9001 |
| Synonyme | Daunorubicin Hydrochloride Imp. D (EP), Daunorubicin Imp. D (EP), Epirubicin Hydrochloride Imp. C (EP), Epirubicin Imp. C (EP), 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)-, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)-, Adriamycin, hydrochloride, ADM hydrochloride, ADR, Adriablastina CS, Adriacin, Adriamycin, Adriblastin, Adriblastina, Adriblastina RD, DOX HCl, Doxorubicin Hydrochloride, FI 106, FI 6804, Hydroxydaunorubicin hydrochloride, Lipo-Dox, Daunorubicin Hydrochloride Impurity D as Hydrochloride, Epirubicin Hydrochloride Impurity C as Hydrochloride, Daunorubicin Impurity D as Hydrochloride, Epirubicin Impurity C as Hydrochloride |
| Formule InChI | InChI=1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1 |
| Type de solution | Neat |
| SMILES | Cl.COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?